(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor ...
The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...
AstraZeneca (NASDAQ:AZN) has announced positive results from a late-stage trial testing Imfinzi (durvalumab) combined with ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known ...
This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...
To our knowledge, SunRISe-4 shows, for the first time, a benefit of the addition of the localised TAR-200 gemcitabine intravesical system to systemic checkpoint inhibition as neoadjuvant treatment in ...
Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...
Bladder cancer imaging and diagnosis have evolved significantly with the integration of advanced magnetic resonance imaging (MRI) techniques and artificial intelligence (AI)-driven analytical methods.
Bladder cancer continues to pose a significant clinical challenge, with accurate imaging and treatment evaluation remaining pivotal in guiding patient management. Recent advances in imaging techniques ...